French-based ‘Live Biotherapeutic’ Company Biose to open their first US office in Cambridge

French-based ‘Live Biotherapeutic’ Company Biose to open their first US office in Cambridge

Announcement comes during 2016 BIO International Convention in San Francisco

Maxence Desjonquères (far left), CEO of Biose, meets with Massachusetts life sciences and economic development leaders in the Massachusetts Pavilion at the BIO 2016 Convention in San Francisco, including (from left to right) Travis McCready, President & CEO of the Massachusetts Life Sciences Center, Lisa Hemmerle, Director of Economic Development for the City of Cambridge, Pamela Norton, Vice President for Industry Relations & Programs at the Massachusetts Life Sciences Center, and Jay Ash, Massachusetts Secretary for Housing & Economic Development.  Not pictured but participating in the meeting was MassBio President & CEO Bob Coughlin.

San Francisco, CA - BIOSE®, a French pharmaceutical company, the Massachusetts Life Sciences Center, and MassBio announced today that BIOSE® is opening their first US office in Cambridge, Massachusetts at the Cambridge Innovation Center.  BIOSE®’s mission is to design and market the best live biotherapeutic products to improve human health. Their Massachusetts office will primarily focus on licensing activities.

BIOSE® has spent the past 50 years working in the Gynecology, Infectology and Gastroenterology sectors in Europe, South America and South-East Asia. BIOSE® has clinical proof of concept in multiple therapeutic areas and a microbiota-centered pipeline, containing as of today more than 15 therapeutic projects in areas including clostridium difficile infection, necrotizing enterocolitis, metformin associated diarrhea and recurrent vulvovaginal candidiasis, for which they have reached human proof of concept and are ready for licensing.

“The life sciences cluster continues to grow in Massachusetts, and we are excited to welcome Biose into the fold,” said Governor Charlie Baker. “The increasing number of global companies making Massachusetts their U.S. headquarters is a testament to the strength of the ecosystem we have built, the unbeatable talent and the bright future of life sciences in the Commonwealth.”

“When we decided to open a subsidiary in the US, the Boston area was a clear choice for us,” said Maxence Desjonquères, CEO of Biose.  “From a business perspective it is one of the leaders worldwide for the biotech and pharmaceutical industry, with all of the potential partners we need to develop and advance our R&D projects.  On a practical point, the Boston area is the best place to be in the US while staying connected with Europe.  With only a 7 hour flight and a manageable time difference with France, our French team and American team will be easily able to work together!”

“We welcome Biose to Massachusetts and look forward to the contributions they will make here to the growing field of microbiota-related therapeutics,” said Travis McCready, president & CEO of the Massachusetts Life Sciences Center. “Biose will join a growing pool of companies and researchers that are working in this exciting space in Massachusetts.”

“We are thrilled to welcome Biose to Massachusetts and we congratulate them on establishing their first US office in Cambridge,” said Robert K. Coughlin, President & CEO of MassBio. “We know that Biose will bring value to and benefit from our robust life sciences community as they continue to grow and connect with new partners.”

“We are so excited to welcome Biose to Cambridge, the Life Sciences Corridor, and the Commonwealth,” said Lisa Hemmerle, Director of Economic Development for the City of Cambridge.  “It is companies like Biose that continue to make this area a world-leading life sciences ecosystem.”